Associated Papers
An evolutionarily conserved salt bridge stabilizes the active site for GTP hydrolysis in Rho GTPases.
Marcus K et al.
The Journal of Biological Chemistry, 2026
Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma.
Mao Y et al.
Npj Precision Oncology, 2026
Rac1 selectively binds a specific lamellipodin isoform via a noncanonical helical interface.
Gao T et al.
The Journal of Biological Chemistry, 2026
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
Foth M et al.
Biorxiv : the Preprint Server for Biology, 2025
Genetic diversity in melanomagenesis: a comprehensive analysis of BRAF, NRAS, KIT and novel mutations across melanoma subtypes.
Göze ÖF et al.
Bmc Cancer, 2025
Comprehensive molecular characterization of Rho GTPases and their regulators across human cancers.
Luo S et al.
International Journal of Cancer, 2025
Molecular mechanism of self-activation induced by the intrinsically disordered region in Rac1b: Structural and functional insights.
Li S et al.
Colloids and Surfaces. B, Biointerfaces, 2025
New insights into the classification of the RAC1 P29S hotspot mutation in melanoma as an oncogene.
Mirzaiebadizi A et al.
Cancer Gene Therapy, 2025
Undifferentiated Melanoma: A Clinicopathologic and Gene Expression Analysis Study With Identification of HMGA2 as a Diagnostic Marker.
Fischer GM et al.
The American Journal of Surgical Pathology, 2025
Somatic mutation and selection at population scale.
Lawson ARJ et al.
Nature, 2025
Tumor-derived RAC1A159V mutation promotes an immunosuppressive microenvironment that represses response to immune checkpoint inhibitor.
Cai M et al.
Science Advances, 2025
A structurally informed human protein-protein interactome reveals proteome-wide perturbations caused by disease mutations.
Xiong D et al.
Nature Biotechnology, 2025
Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review.
Cosci I et al.
Pharmaceuticals (basel, Switzerland), 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Comprehensive Genomic Profiles of Melanoma in Veterans Compared to Reference Databases.
Mettman D et al.
Federal Practitioner : for the Health Care Professionals of the Va, Dod, and Phs, 2025
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.
Weller C et al.
Science (new York, N.y.), 2025
Analysis of Variants Induced by Combined Ex Vivo Irradiation and In Vivo Tumorigenesis Suggests a Role for the ZNF831 p.R1393Q Variant in Cutaneous Melanoma Development.
Usoltsev D et al.
The Journal of Investigative Dermatology, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration.
Gadal S et al.
Cancer Research, 2025
Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma.
Ford CA et al.
Cancer Research, 2025
RAC1-Amplified and RAC1-A159V Hotspot-Mutated Head and Neck Cancer Sensitive to the Rac Inhibitor EHop-016 In Vivo: A Proof-of-Concept Study.
Chan HHY et al.
Cancers, 2025
Exploring the Common Mutational Landscape in Cutaneous Melanoma and Pancreatic Cancer.
Broseghini E et al.
Pigment Cell & Melanoma Research, 2025
Pan-cancer analyses identify oncogenic drivers, expression signatures, and therapeutic vulnerabilities in RHO GTPase pathway genes.
Fernández R et al.
Frontiers in Bioinformatics, 2025
Assessing the Mechanism of Rac1b: An All-Atom Simulation Study of the Alternative Spliced Variant of Rac1 Small Rho GTPase.
Cresca S et al.
Journal of Chemical Information and Modeling, 2024
A Comparative Genomic Study of Conventional and Undifferentiated Melanoma.
Fischer GM et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2024
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution.
Nguyen DD et al.
Nature, 2024
Hallmarks of a genomically distinct subclass of head and neck cancer.
Muijlwijk T et al.
Nature Communications, 2024
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
Melanoma genomics - will we go beyond BRAF in clinics?
Mirek J et al.
Journal of Cancer Research and Clinical Oncology, 2024
Tumor-derived RHOA mutants interact with effectors in the GDP-bound state.
Lin Y et al.
Nature Communications, 2024
Genomic alterations in two patients with esophageal carcinosarcoma identified by whole genome sequencing: a case report.
Inoue M et al.
Surgical Case Reports, 2024
Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma.
Sementsov M et al.
Embo Molecular Medicine, 2024
Integrative genomic analysis reveals cancer-associated mutations in patients with ophthalmic tumors.
Zhu F et al.
The Journal of International Medical Research, 2024
Tumorigenesis driven by the BRAFV600E oncoprotein requires secondary mutations that overcome its feedback inhibition of migration and invasion.
Gadal S et al.
Biorxiv : the Preprint Server for Biology, 2024
Assessing the mechanism of fast-cycling cancer-associated mutations of Rac1 small Rho GTPase.
Parise A et al.
Protein Science : a Publication of the Protein Society, 2024
Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.
Haugh AM et al.
Cancers, 2024
A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance.
Scaini MC et al.
Npj Precision Oncology, 2024